Clinical Trial Update: Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. [Phase 3]

View source ↗

Summary

Open-label extension study of Zigakibart in adults with Immunoglobulin A nephropathy is in Phase 3 and currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunoglobulin Nephropathy

Drugs mentioned

• Zigakibart

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Kidney Diseases, Kidney Diseases, Chronic | Phase 3 | Status: RECRUITING